Irina Grishina

HCPs: Early diagnosis is critical in managing a #RareDisease like primary #hyperoxaluria type 1 (PH1). Left undiagnosed, patients are at increased risk for serious downstream health complications. Learn more from Dr. David J. Sas, pediatric nephrologist, in an episode of Medical Stories airing on PBS stations. https://bit.ly/3ATSDVR

132

In 2024, 5 emerging BTK inhibitors are undergoing late-phase clinical investigation for #multiplesclerosis. Most clinicians are likely unaware of the clinical data regarding their use in MS. Dive into the data and earn free #CME here: https://bit.ly/4gViIVp #MedEd #FOAMed

2

ASCO 2024 | IMFINZI poised for breakthrough in limited-stage small cell lung cancer: Could be the pioneer for the treatment AstraZeneca’s IMFINZI, already approved for extensive-stage small cell lung cancer, is now being investigated as a consolidation treatment for limited-stage patients. Although limited-stage small cell lung cancer represents a smaller patient population, the results for IMFINZI are highly anticipated. If successful, IMFINZI could become the first drug approved for this specific indication, significantly enhancing patient care. For exclusive insights on small-cell lung cancer treatment, visit: https://lnkd.in/g7KPDC-9 #AstraZeneca #IMFINZI #SmallCellLungCancer #LungCancerTreatment #CancerResearch #Oncology #ClinicalTrials #PharmaInnovation #PatientCare #CancerBreakthrough #Healthcare #MedicalResearch #LimitedStageCancer #PharmaNews #DrugApproval

17

Bimagrumab may be a game-changer for obesity and type 2 diabetes. In a recent phase II trial, 75 overweight/obese patients with T2DM got monthly injections x48 weeks, with a remarkable 20.5% ▼ in total body fat mass, & 3.6% ▲ in lean mass. More at: https://buff.ly/3WEKTji

5

Congratulations to the Tagrisso team at AstraZeneca and lead investigator Dr. Suresh S. Ramalingam, MD for the incredible results of the phase III LAURA trial! The LAURA trial found that patients with unresectable stage 3 EGFR-mutated non-small cell lung cancer (NSCLC) who received Tagrisso lived a median of 39.1 months without disease progression versus 5.6 months for placebo. Two years after treatment, 6% of patients on Tagrisso developed brain metastases compared with 28% in the control group. The tumor progression benefit was seen across key subgroups, including in stage 3a and in stage 3b or 3c tumors. For an overview of the findings, take a look at Fierce Pharma's recap of the presentation delivered at the American Society of Clinical Oncology (ASCO)'s 2024 meeting. The full study was published by NEJM Group. https://lnkd.in/gBF6HEYf #lungcancer #cancerresearch #lungcancerawareness https://lnkd.in/eyBPWbhu

3

2 Comments

🌐 ONO Pharmaceutical Acquires Deciphera for $2.4 Billion, Expanding Cancer Care Horizons! 🧬 ONO PHARMA USA has made a strategic move by acquiring Deciphera Pharmaceuticals for $2.4 billion. Deciphera, now operating as an independent subsidiary from its Waltham headquarters, brings its specialized cancer treatments and research into ONO’s portfolio. This deal involves a 74.7% premium on Deciphera's last share price, highlighting ONO's commitment to enhancing its oncology offerings. Among the standout products from Deciphera is QINLOCK, approved for treating gastrointestinal stromal tumors in over 40 countries, along with promising candidates like vimseltinib. ONO's CEO, Gyo Sagara, commented, "This acquisition enlarges our oncology portfolio and propels our business development in key markets. We admire Deciphera’s innovative spirit and look forward to our joint future." Steve Hoerter, CEO of Deciphera, shared, "This partnership boosts our ability to enhance cancer care, delivering significant value and hope." Discover more about this transformative deal here: https://lnkd.in/g4-gk3St Stay at the forefront of pharmaceutical innovations by following World Pharmaceutical Frontiers. #Oncology #Pharmaceuticals #HealthcareInnovation #MergersAndAcquisitions #WorldPharmaceuticalFrontiers 🌍

5

Today MAIA is presenting a late breaking abstract providing updates from THIO-101 Phase 2 #clinicaltrial in #NSCLC at #SITC2024. CEO Vlad Vitoc, MD, MBA comments, “We are honored to have our THIO-101 data recognized by SITC in a late-breaking abstract, a category reserved for research that has the potential to change medical practices. We believe that our latest data is compelling and further supports the ability of THIO to produce cancer cell specific immune memory and to remain active against cancer cells after extended periods of time. Our findings to date are particularly significant for advanced-stage patients resistant to CPI and chemotherapy treatments who are in desperate need of new treatment options. In our opinion, the combination of THIO with a CPI is showing promise as a durable and effective NSCLC treatment.” If you’re attending, presentation details may be found here: https://bit.ly/4fzZEu4 #Biotech Society for Immunotherapy of Cancer (SITC)

15

Can Johnson & Johnson's subcutaneous (SC) Rybrevant take on AstraZeneca’s Tagrisso in #NSCLC? To find out we are asking an expert. Learn more here: https://lnkd.in/dyvzkEmx #cancer #clinicalresearch #clinicaltrials #lungcancer #oncology #pharmaceuticals

6

Biosimilars are changing the landscape of treatment for cancer, inflammation, and more. These FDA-approved biologics offer a promising pathway to lower healthcare costs. Connect with our team to learn how Amplify Rx is leading the charge in biosimilar adoption. #Biosimilars #HealthcareInnovation #AmplifyRx"

6

ICYMI: We presented new Phase 3 data for our investigational medicine for the treatment of hereditary angioedema (#HAE) during a late-breaking session at the 2024 European Academy of Allergy and Clinical Immunology - EAACI Congress, which was simultaneously published in The New England Journal of Medicine. HAE is a rare and life-threatening genetic condition that involves recurrent attacks of severe swelling in various parts of the body, which can cause severe pain and significantly disrupt daily life.    We’re committed to advancing research to better understand how to improve the lives of people living with this #RareDisease, which affects about 20,000 people across the U.S. and Europe. #EAACIcongress 

198

1 Comment

Human error happens. But for a clinical trial to run successfully, investigational products can’t be misplaced.  👉 In our ultimate guide to RTSM, we discuss why automating supply chain tasks and randomizations is essential as clinical trials become more complex: https://bit.ly/4dW7DSm #RTSM #ClinicalTrials #DataQuality #PatientCentricity

22

Understanding the unique challenges facing Biotech sponsors who are embarking on IO clinical studies, IQVIA Biotech’s Erin Finot, MS, MBA recently authored a compelling white paper reviewing IO innovation in cell and gene therapies. If you’re heading to ASCO, this is your chance to meet with our VP of Immuno-Oncology and Cell and Gene Therapy, and discuss your specific clinical challenges. Discover more. https://bit.ly/4dRSvp4 #ASCO24

42

Merck's subcutaneous pembrolizumab shows promise in matching IV KEYTRUDA for NSCLC, offering faster administration and enhanced patient comfort. A potential game-changer in cancer care accessibility! #CancerTreatment #Pharma #Oncology #RegulatoryAgencies #PharmaceuticalCompanies #Innovation #ClinicalResearches #MarketAccessToday #MarketAccess

7

Is Data Lake the piece of puzzle that was missing in the clinical validation stage? 🧩 📚 Learn more about what is important in research and how Data Lake fits into it from our CEO Wojciech Sierocki, MD.

7

In Part 3 of our exclusive series 🎥, Brian Burkhardt, Co-Founder and Executive Director of the Oliver Patch Project, shares the story behind the impactful partnership with Innovative Trials and how the idea came about. Learn how the Retention Patch Program was born and how it’s transforming patient retention in clinical trials 🤝. Don’t miss the final chapter of this series—watch now and scan the QR code to dive deeper! 👇 #OliverPatchProject #InnovativeTrials #ClinicalTrials #PatientRetention #NonProfit #HealthcareInnovation #ResearchForGood #OPP #RetentionPatchProgram #RPP #patientrecruitment

5